Mohammed Hasan Khan1, Surabhi Pathak2, Udit Yadav3, Yogita Rochlani4, Wilbert S Aronow5. 1. King's Daughters Medical Center, Ashland, KY, USA. mhasan87@gmail.com. 2. King's Daughters Medical Center, Ashland, KY, USA. 3. Northern Alabama Medical Center, Florence, AL, USA. 4. Montefiore Medical Center, Bronx, NY, USA. 5. New York Medical College at Westchester Medical Center, Valhalla, NY, USA.
Abstract
PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of cancer recurrence. We then discuss the latest concepts regarding the pathophysiology of hypertension in cancer survivors in detail. There is a focus on inflammation and the role it plays in cancer and hypertension followed by a brief discussion on clonal hematopoiesis of indeterminate potential (CHIP) and associated hypertension. There is a brief review of various cancer therapies associated with development and worsening of hypertension control and the underlying mechanisms behind this. We conclude the review article by giving recommendations on blood pressure control in this unique patient population. RECENT FINDINGS: A lot of newer anti-cancer therapies have been implicated in the development or worsening of hypertension. We summarize the latest data, explore associations between these therapies and hypertension, and review the latest understanding of the underlying mechanisms driving this process. Hypertension is a major risk factor for cardiovascular disease in cancer survivors and must be recognized and treated promptly.
PURPOSE OF REVIEW: With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hypertension is a major risk factor for cardiovascular disease and has a higher prevalence in cancer survivors compared to the general population. In this review article, we discuss the burden of hypertension in cancer survivors and how this impacts their long-term outcomes and risk of cancer recurrence. We then discuss the latest concepts regarding the pathophysiology of hypertension in cancer survivors in detail. There is a focus on inflammation and the role it plays in cancer and hypertension followed by a brief discussion on clonal hematopoiesis of indeterminate potential (CHIP) and associated hypertension. There is a brief review of various cancer therapies associated with development and worsening of hypertension control and the underlying mechanisms behind this. We conclude the review article by giving recommendations on blood pressure control in this unique patient population. RECENT FINDINGS: A lot of newer anti-cancer therapies have been implicated in the development or worsening of hypertension. We summarize the latest data, explore associations between these therapies and hypertension, and review the latest understanding of the underlying mechanisms driving this process. Hypertension is a major risk factor for cardiovascular disease in cancer survivors and must be recognized and treated promptly.
Authors: Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-06-11 Impact factor: 508.702
Authors: Gregory S Calip; Kathleen E Malone; Julie R Gralow; Andy Stergachis; Rebecca A Hubbard; Denise M Boudreau Journal: Breast Cancer Res Treat Date: 2014-10-10 Impact factor: 4.872
Authors: Zhaoming Wang; Stephen V Rice; Ti-Cheng Chang; Yu Liu; Qi Liu; Na Qin; Daniel K Putnam; Kyla Shelton; Jennifer Q Lanctot; Carmen L Wilson; Kirsten K Ness; Michael C Rusch; Michael N Edmonson; Gang Wu; John Easton; Chimene A Kesserwan; James R Downing; Xiang Chen; Kim E Nichols; Yutaka Yasui; Leslie L Robison; Jinghui Zhang Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 11.816